Exciting news in Europe! The CHMP recommends our subcutaneous therapy for patients with advanced #NSCLC with certain EGFR mutations. Read about this potential new option that can improve the treatment experience for patients: bit.ly/3Q0V5OH

Today, we’re one step closer to transforming care for EGFR-mutated #NSCLC. I’m excited to share that the European Commission has now fully approved our chemotherapy-free regimen—a breakthrough that offers a new way forward for patients and their families across the EU: bit.ly/3E3RBbC

Proud to share a topline overall survival announcement from the Phase 3 MARIPOSA trial in EGFR-mutated #NSCLC. These data reinforce Johnson and Johnson Innovative Medicine's dedication to help transform what’s possible in cancer care and potentially give patients more time and hope: bit.ly/4a3Dwa9

Excited to announce the European Commission approved our chemotherapy-free combination therapy for the first-line treatment of EGFRm #NSCLC. Proud to be part of a team at #JNJOncology that continues to drive innovation for patients.

bit.ly/4gz7u8k